Rapid Therapeutic Science Laboratories, Inc. (RTSL) Research

Rapid Therapeutic Science Laboratories, Inc. (RTSL) is a biotechnology firm specializing in the aerosolized delivery of non-psychoactive cannabinoids directly into the bloodstream. This innovative approach is aimed at treating various conditions, including chronic pain, post-traumatic stress disorder (PTSD), insomnia, and aiding in surgery recovery, among other health issues. RTSL's product portfolio features pressurized meter dose inhalers (MDIs), designed to precisely dispense an aerosolized mist into the lungs, alongside sublingual oral spray devices. Furthermore, the company offers water-soluble cannabidiol (CBD) and cannabigerol (CBG) isolates under its "nhaler" brand. Established in 2013 and based in Dallas, Texas, the company adopted its current name, Rapid Therapeutic Science Laboratories, Inc., in January 2020, having previously operated as Holly Brothers Pictures, Inc. It was also formerly a subsidiary of Texas Mdi, Inc.

Market snapshot

Symbol
RTSL
Price
$0.00
Day change
0.00%
Market cap
$883.0
P/E ratio
-0.01x
52-week range
0.0001-0.0074
Sector
Healthcare
Industry
Medical - Devices

Peer companies

  • Hempfusion Wellness Inc. (CBDHF)
  • Cantabio Pharmaceuticals, Inc. (CTBO)
  • Diagnocure, Inc. (DGCRF)
  • Humanigen, Inc. (HGENQ)
  • MagForce AG (MGFRF)
  • NutraLife BioSciences, Inc. (NLBS)
  • NMC Health plc (NMMCF)
  • Nanomix Corporation (NNMX)

Recent insider activity

  • Justin Scott Suggs — trade (0 shares) on 2021-08-03
  • Berrier Sean Paul — G-Gift (2000000 shares) on 2021-12-27
  • Schmidt Donal Ray Jr. — G-Gift (2000000 shares) on 2021-12-27
  • Punzi Henry Anthony — trade (0 shares) on 2021-08-27
  • Punzi Henry Anthony — trade (0 shares) on 2021-08-27

Open Rapid Therapeutic Science Laboratories, Inc. (RTSL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.